Csm Bruker ANPC COVID 19 4 785b89d25c

Our customers and solutions in front line response to COVID-19 threat

News related to COVID-19

Virologists and Lung Disease Specialists Commission Bruker´s micro-CT for some of the World’s First in vivo COVID-19 Imaging Experiments

Virologists microCT

Bruker's BioSpin PreClinical Imaging Division reports the use of the Bruker SkyScan 1278 in vivo micro-CT system at the KU Leuven, Belgium, to support COVID-19-focused research. This research will leverage the university's expertise in preclinical testing to study the efficacy of vaccine and drug candidates in COVID-19 infection models.

Antimicrobial Coatings Used to Reduce the Presence of Surface Germs are Monitored for Efficacy with Portable XRF Technology

Banner Antimicrobial Coatings

Allied BioScience develops innovative solutions to create cleaner human environments.  They began using Bruker's Handheld XRF in 2018 to develop methods and presented their findings to predict the efficacy of an antimicrobial surface coating utilizing X-ray Fluorescence Spectroscopy (XRF) at IDWeek 2019.

Bruker partners with ANPC to support major new frontline response to combat the COVID-19 threat

Bruker partners with ANPC to combat COVID-19 threat

The ANPC team, led by world-renowned phenomics pioneer and academician Professor Jeremy Nicholson, and working with the South Metropolitan Health Service COVID-19 Response Team and the broader Western Australian (WA) healthcare community, has launched a major research and diagnostics project to better understand and predict variation in COVID-19 severity and determine the complex genetic, environmental and lifestyle interactions that influence its pathogenicity in individuals. Later they will engage with clinical trials of novel antiviral agents and when available vaccines in order to predict responder/non-responder outcomes.

Bruker MicroCT Systems Supporting Quality Control for Refurbished FFP Masks

Mask QC banner

In the effort to tackle the coronavirus pandemic, Bruker is extremely proud that its instruments are being used to ensure quality levels of reprocessed filtering face pieces (FFP) commonly known as facemasks.

Metabolomics and Traditional Chinese Medicine in the treatment of viral pneumonia

Chinese medicine

Traditional Chinese Medicines (TCMs) are widely used throughout the world in the prevention and treatment of viral pneumonia through the belief in their potential to boost the body's resistance to the pneumonia virus and modulate its immune response. Many viruses have established sophisticated mechanisms to interact with the host immune system.

Bruker is happy to be a partner and is encouraging scientists to join the the COVID-19 NMR initiative

COVID-19 NMR

The aim of COVID19-NMR is to determine RNA and protein structures of SARS-CoV-2 and to investigate the drugability of those structures by small molecules. Bruker is happy to provide measurement time on high performance NMR systems as well as sample automation capabilities to enhance productivity with scientists driving COVID-19 research from home.  

Plasma Metabolomics Shows Promise in H1N1 Influenza Pneumonia Diagnosis and Prognosis

Pneumonia

Influenza remains the predominant viral cause of community-acquired pneumonia (CAP) in adults. The World Health Organization estimates that annual influenza epidemics result in about 3-5 million cases of severe illness and about 250,000 to 500,000 deaths worldwide.

Webinars related to COVID-19

Treatments of COVID-19: Old Drugs, New Tricks

Banner webinar april 21 nuovo

COVID-19 is a global pandemic caused by the SARS-CoV-2 virus. There is a huge worldwide effort underway to discover vaccines and new drugs, and to repurpose old drugs to treat this disease. This talk will discuss the drugs that are currently being used to treat COVID-19: remdesivir, chloroquine and the combination of lopinavir/ritonavir.

Speaker: Niamh O’Boyle, Trinity College, Dublin

 

View webinar

NMR Characterisation of Polysaccharide-Based Vaccines

Banner covid 2

Polysaccharide-protein conjugate vaccines are among the safest and most successful vaccines developed during the last 30 years. Since the first semisynthetic chemical conjugate vaccine licensed in the 1980’s to protect human against Haemophilus influenzae type b infection, conjugate vaccines against Neisseria meningitidis and Streptococcus pneumoniae have been developed and registered using the same approach (i.e. bacterial growth to produce capsular polysaccharide antigen and chemical coupling to carrier protein).

Speaker: Francesco Berti, GSK Siena, Italy

 

Register

Novel Method for Superior Lead Optimisation – Application to the Antiviral AZT

Banner covid 3

Speaker: Armando Navarro, UFPE, Brazil

 

Register

Upcoming

May 26 - Antibodies

Banner may 26

Speaker: Maurizio Muroni, AstraZeneca, Cambridge UK

 

Register

September 08 - Biotherapeutic Proteins

Banner sept 08

Speaker: Joan Malmstron, Novo Nordisk, Denmark

 

Register